Terms: = Breast cancer AND FES, FPS, 2242, ENSG00000182511, P07332 AND Prognosis
20 results:
1. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract] [Full Text] [Related]
2. The Clinicopathological Features and Prognostic Significance of HER2-Low in Early breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative breast cancer Stratified by Hormone Receptor Status.
Gamrani S; Akhouayri L; Boukansa S; Karkouri M; El Fatemi H
Breast J; 2023; 2023():6621409. PubMed ID: 38075551
[TBL] [Abstract] [Full Text] [Related]
3. The Application of 18 F-fes PET in Clinical cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract] [Full Text] [Related]
4. Near-Infrared Phototheranostic Iron Pyrite Nanocrystals Simultaneously Induce Dual Cell Death Pathways via Enhanced Fenton Reactions in Triple-Negative breast cancer.
Zhao C; Liu Z; Chang CC; Chen YC; Zhang Q; Zhang XD; Andreou C; Pang J; Liu ZX; Wang DY; Kircher MF; Yang J
ACS Nano; 2023 Mar; 17(5):4261-4278. PubMed ID: 36706095
[TBL] [Abstract] [Full Text] [Related]
5. 16α-18F-fluoro-17β-Fluoroestradiol (fes): Clinical Applications for Patients With breast cancer.
Ulaner GA
Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
[TBL] [Abstract] [Full Text] [Related]
6. Pregnancy outcomes in children, adolescents, and young adults that survived cancer: A nationwide survey in Japan.
Yasuoka T; Iwama N; Ota K; Harada M; Hasegawa J; Yaegashi N; Sugiyama T; Suzuki N; Osuga Y
J Obstet Gynaecol Res; 2021 Sep; 47(9):3352-3361. PubMed ID: 34155729
[TBL] [Abstract] [Full Text] [Related]
7. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Barin-Le Guellec C; Lafay-Chebassier C; Ingrand I; Tournamille JF; Boudet A; Lanoue MC; Defossez G; Ingrand P; Perault-Pochat MC; Etienne-Grimaldi MC
Eur J Cancer; 2020 Jan; 124():37-46. PubMed ID: 31715555
[TBL] [Abstract] [Full Text] [Related]
8. Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity.
Jia X; Li C; Li L; Liu X; Zhou L; Zhang W; Ni S; Lu Y; Chen L; Jeong LS; Yu J; Zhang Y; Zhang J; He S; Hu X; Sun H; Yu K; Liu G; Zhao H; Zhang Y; Jia L; Shao ZM
Clin Cancer Res; 2019 Jun; 25(12):3658-3672. PubMed ID: 30833270
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Potential of Estrogen and Progesterone Receptor Imaging.
Linden HM; Peterson LM; Fowler AM
PET Clin; 2018 Jul; 13(3):415-422. PubMed ID: 30100079
[TBL] [Abstract] [Full Text] [Related]
10. fes-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.
Stanicka J; Rieger L; O'Shea S; Cox O; Coleman M; O'Flanagan C; Addario B; McCabe N; Kennedy R; O'Connor R
Oncogene; 2018 Jun; 37(23):3131-3150. PubMed ID: 29540831
[TBL] [Abstract] [Full Text] [Related]
11. [Advances on correlation of PET-CT findings with breast cancer molecular subtypes, treatment response and prognosis].
Pan J; He M; Ke W; Hu M; Wang M; Shen P
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 May; 46(5):473-480. PubMed ID: 29488712
[TBL] [Abstract] [Full Text] [Related]
12. A preliminary study of
Gong C; Yang Z; Sun Y; Zhang J; Zheng C; Wang L; Zhang Y; Xue J; Yao Z; Pan H; Wang B; Zhang Y
Sci Rep; 2017 Jul; 7(1):6584. PubMed ID: 28747642
[TBL] [Abstract] [Full Text] [Related]
13. The Prognostic and Clinicopathological Significance of Tumor-Associated Macrophages in Patients with Gastric cancer: A Meta-Analysis.
Yin S; Huang J; Li Z; Zhang J; Luo J; Lu C; Xu H; Xu H
PLoS One; 2017; 12(1):e0170042. PubMed ID: 28081243
[TBL] [Abstract] [Full Text] [Related]
14. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Liao GJ; Clark AS; Schubert EK; Mankoff DA
J Nucl Med; 2016 Aug; 57(8):1269-75. PubMed ID: 27307345
[TBL] [Abstract] [Full Text] [Related]
15. PET Imaging of breast cancer: Role in Patient Management.
Lebron L; Greenspan D; Pandit-Taskar N
PET Clin; 2015 Apr; 10(2):159-95. PubMed ID: 25829085
[TBL] [Abstract] [Full Text] [Related]
16. [Imaging of cancer activity and range of tumor involvement--applying to breast cancer].
Shibata K; Uno K; Wu J; Ko W
Rinsho Byori; 2007 Jul; 55(7):648-55. PubMed ID: 17718061
[TBL] [Abstract] [Full Text] [Related]
17. Biological characterisation of breast cancer by means of PET.
Buck AK; Schirrmeister H; Mattfeldt T; Reske SN
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S80-7. PubMed ID: 15127240
[TBL] [Abstract] [Full Text] [Related]
18. prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer.
Gruber G; Ciriolo M; Altermatt HJ; Aebi S; Berclaz G; Greiner RH
Int J Cancer; 2004 Mar; 109(1):144-8. PubMed ID: 14735481
[TBL] [Abstract] [Full Text] [Related]
19. PET in breast cancer.
Flanagan FL; Dehdashti F; Siegel BA
Semin Nucl Med; 1998 Oct; 28(4):290-302. PubMed ID: 9800236
[TBL] [Abstract] [Full Text] [Related]
20. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract] [Full Text] [Related]
